Schedule 13G ownership disclosure

CRINETICS PHARMACEUTICALS INC

Common Stock · CUSIP: 22663K107

Event date: 2024-12-31

Filing-level shares
9,089,391
Percent of class
9.8%
  • The Vanguard Group

    Shares: 9,089,391 · Class: 9.8%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000932471-25-000094
Form type
SCHEDULE 13G/A
Filer
Crinetics Pharmaceuticals, Inc.
CIK
CIK 1658247
Filed
Jan 30, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub